The National Cancer Institute is offering a grant to accelerate the adoption and validation of markers and assays for cancer detection, diagnosis, prognosis, and monitoring. This opportunity includes validating markers for treatment response, toxicity, prevention, and control. Applicants must have analytically validated assays for intended clinical use. The focus is on developing multiple assays for measuring various markers, including immune markers. Closing date: Oct 08, 2020.
Opportunity ID: 297926
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-18-310 |
| Funding Opportunity Title: | Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 – Clinical Trials Not Allowed |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 12, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Oct 08, 2020 |
| Current Closing Date for Applications: | Oct 08, 2020 |
| Archive Date: | Nov 13, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $250,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Private institutions of higher education Public housing authorities/Indian housing authorities State governments City or township governments Independent school districts For profit organizations other than small businesses County governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-18-310.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00235419 | Oct 27, 2017 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00260121 | Jan 14, 2018 | Oct 08, 2020 | View |
Package 1
Mandatory forms
297926 RR_SF424_2_0-2.0.pdf
297926 PHS398_CoverPageSupplement_4_0-4.0.pdf
297926 RR_OtherProjectInfo_1_4-1.4.pdf
297926 PerformanceSite_2_0-2.0.pdf
297926 RR_KeyPersonExpanded_2_0-2.0.pdf
297926 RR_Budget_1_4-1.4.pdf
297926 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
297926 RR_SubawardBudget30_1_4-1.4.pdf
297926 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
297926 RR_SF424_2_0-2.0.pdf
297926 PHS398_CoverPageSupplement_5_0-5.0.pdf
297926 RR_OtherProjectInfo_1_4-1.4.pdf
297926 PerformanceSite_2_0-2.0.pdf
297926 RR_KeyPersonExpanded_2_0-2.0.pdf
297926 RR_Budget_1_4-1.4.pdf
297926 PHS398_ResearchPlan_4_0-4.0.pdf
297926 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
297926 RR_SubawardBudget30_1_4-1.4.pdf
297926 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
